Dr Aparna Rao
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
26 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study
DOI: 10.1136/jitc-2025-0145642025
Journal article
1636P Gonadal toxicity in men receiving immune checkpoint inhibitors for melanoma
DOI: 10.1016/j.annonc.2025.08.22642025
Journal article
Conservation and divergence of metabolic phenotypes between patient tumours and matched xenografts
DOI: 10.1038/s42255-025-01338-22025
Journal article
Patient-reported acute and chronic toxicities from adjuvant therapies post resection of melanoma.
DOI: 10.1200/jco.2025.43.16_suppl.e215682025
Conference Proceedings
Financial toxicity and employment outcomes in people with melanoma receiving adjuvant therapies.
DOI: 10.1200/jco.2025.43.16_suppl.95772025
Research grants (ARC, NHMRC, MRFF)
Identifying Novel Metabolic Biomarkers and Therapeutic Targets in Patients With Melanoma
2014
Journal article
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
DOI: 10.1158/2159-8290.CD-13-0440
RECENT SCHOLARLY WORKS
2025
Journal article
Anxiety, depression, fear of cancer recurrence (FCR) and health-related quality of life (HRQL) in people with melanoma receiving adjuvant therapies.
DOI: 10.1200/jco.2025.43.16_suppl.95662025
Journal article
High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
DOI: 10.1158/2159-8290.CD-23-13192025
Journal article
Assessing cancer therapeutic efficacy in vivo using [2H7] glucose deuterium metabolic imaging
DOI: 10.1126/sciadv.adr05682024
Journal article
Tissue resident memory (TRM) T cells and dendritic cells form an in situ archetype for improved response to immune checkpoint therapy in metastatic melanoma
DOI: 10.1158/2326-6074.TUMIMM24-A0062024
Journal article
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
DOI: 10.1016/j.ejca.2024.113601